Sanofi builds Chinese research web with rare disease project
This article was originally published in Scrip
Executive Summary
Orphan drugs, the treatments for rare diseases that have long been neglected in China, are slowly gaining attention in the country as multinational companies - many threatened by patent expirations - seek new areas of growth.